About NK1 transcription factor-related protein 2
NK1 transcription factor-related protein 2 (NKX1-2) is a protein
from Homo sapiens identified by UniProt accession
Q9UD57, 310 residues long.
MolForge cross-references it against 0 known binders and
23 disease associations.
Target properties
| Protein name | NK1 transcription factor-related protein 2 |
|---|
| UniProt accession | Q9UD57 |
|---|
| Gene | NKX1-2 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 310 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (23)
Diseases linked to this target (Open Targets).
- ulcer disease · score 0.12
- proctitis · score 0.12
- arterial stiffness measurement · score 0.11
- body height · score 0.08
- risky sexual behaviour measurement · score 0.06
- behavioural disinhibition measurement · score 0.06
- alcohol dependence · score 0.06
- B-cell acute lymphoblastic leukemia · score 0.06
- non-small cell lung carcinoma · score 0.06
- lean body mass · score 0.04
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q9UD57-F1 | alphafold | PREDICTED | 63.35 | — |
Amino-acid sequence (310 residues)
MLAWQDGGAK AAPSHHKISF SVLDILDPQK FTRAALPAVR PAPREARKSL AEVEAGKDAS SRDPVRQLET PDAAGPGAGQ ASPLEGSEAE EEEDAEDPRR PRLRERAARL LPGLARSPDA PAGALASGEP CEDGGGGPVR SPPGSPGSPR PRRRRLEPNC AKPRRARTAF TYEQLVALEN KFRATRYLSV CERLNLALSL SLTETQVKIW FQNRRTKWKK QNPGADGAAQ VGGGAPQPGA AGGGGGGGSG GSPGPPGTGA LHFQTFPSYS AANVLFPSAA SFPLTAAAPG SPFAPFLGPS YLTPFYAPRL
Explore NK1 transcription factor-related protein 2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets